Correlation Between Artiva Biotherapeutics, and Equillium

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Artiva Biotherapeutics, and Equillium at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Artiva Biotherapeutics, and Equillium into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Artiva Biotherapeutics, Common and Equillium, you can compare the effects of market volatilities on Artiva Biotherapeutics, and Equillium and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Artiva Biotherapeutics, with a short position of Equillium. Check out your portfolio center. Please also check ongoing floating volatility patterns of Artiva Biotherapeutics, and Equillium.

Diversification Opportunities for Artiva Biotherapeutics, and Equillium

0.13
  Correlation Coefficient

Average diversification

The 3 months correlation between Artiva and Equillium is 0.13. Overlapping area represents the amount of risk that can be diversified away by holding Artiva Biotherapeutics, Common and Equillium in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Equillium and Artiva Biotherapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Artiva Biotherapeutics, Common are associated (or correlated) with Equillium. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Equillium has no effect on the direction of Artiva Biotherapeutics, i.e., Artiva Biotherapeutics, and Equillium go up and down completely randomly.

Pair Corralation between Artiva Biotherapeutics, and Equillium

Given the investment horizon of 90 days Artiva Biotherapeutics, Common is expected to under-perform the Equillium. In addition to that, Artiva Biotherapeutics, is 1.42 times more volatile than Equillium. It trades about -0.31 of its total potential returns per unit of risk. Equillium is currently generating about 0.09 per unit of volatility. If you would invest  60.00  in Equillium on October 20, 2024 and sell it today you would earn a total of  4.00  from holding Equillium or generate 6.67% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Artiva Biotherapeutics, Common  vs.  Equillium

 Performance 
       Timeline  
Artiva Biotherapeutics, 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Artiva Biotherapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in February 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.
Equillium 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Equillium has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in February 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Artiva Biotherapeutics, and Equillium Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Artiva Biotherapeutics, and Equillium

The main advantage of trading using opposite Artiva Biotherapeutics, and Equillium positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Artiva Biotherapeutics, position performs unexpectedly, Equillium can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Equillium will offset losses from the drop in Equillium's long position.
The idea behind Artiva Biotherapeutics, Common and Equillium pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.

Other Complementary Tools

Transaction History
View history of all your transactions and understand their impact on performance
Global Correlations
Find global opportunities by holding instruments from different markets
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios